SS31
Mitochondria-targeted tetrapeptide that improves mitochondrial function and reduces oxidative stress. FDA-approved (accelerated) for Barth syndrome; investigated in heart failure and other mitochondrial diseases.
Regulatory status (as of Sept 2026)
FDA-approved (accelerated approval, Sept 19 2025) for Barth syndrome only; any other use is off-label/investigational.
See the FDA peptide regulatory tracker · Read our July 27, 2026 dispatch on the FDA PCAC peptide vote4 studies referenced · Last reviewed Oct 1, 2026 · Reviewed by The Peptide Dispatch Editorial Team · How we research & label content
SS-31 (Elamipretide) is an FDA-approved prescription drug. Mitochondria-targeted tetrapeptide that improves mitochondrial function and reduces oxidative stress.
| Half-life | Not established in published research detailsNo published PK data found (HFrEF 4-h IV infusion: peak at end-infusion, undetectable by 24 h) |
|---|---|
| How it's given in studies | Subcutaneous or IV injection |
| Research stage | FDA-approved |
| Dosing | Published research: HFrEF: single 4-h IV infusion 0.005, 0.05, 0.25 mg/kg/h detailsHFrEF: single 4-h IV infusion 0.005, 0.05, 0.25 mg/kg/h; Barth syndrome (TAZPOWER): daily SC injection.Community-reportedCommunity-reported: 0.25–4 mg/kg, subcutaneous or IV injection |
Published-research dosing is what was given in the cited studies (species and units as reported). Community-reported dosing is what users describe, not from clinical studies. Neither is a recommendation. Not medical advice.
Where each point comes from: Clinicalhuman trials and FDA labels Lab / animalrodent, cell and ex vivo studies Community-reporteduser experience and commonly used protocols, not from clinical studies
In plain terms: It targets a fat molecule inside mitochondria, the cell's power plants, and is approved for one rare disease (Barth syndrome). Targets cardiolipin in the inner mitochondrial membrane and is proposed to stabilize electron transport and reduce ROS production (mechanism review, Sabbah 2025). It received FDA accelerated approval for Barth syndrome, a disorder of cardiolipin remodelling (Zhao 2026).
How to read this: Each item below is an effect observed in research subjects in the cited studies — think of Dexter, our stand-in research subject. These are findings from the literature, not results you should expect, and not medical advice.
Community-reportedIn user communities, SS-31 (Elamipretide) is typically run at 0.25–4 mg/kg (subcutaneous or IV injection). This is not a recommendation.
Community reports are anecdotal, vary widely in product quality and purity, and are not medical advice. Talk to a licensed provider.
New research, FDA peptide updates, and what users are reporting. One email a week. Unsubscribe anytime.
| Peptide | Half-Life | Route | Research Status |
|---|---|---|---|
| SS-31 (Elamipretide) | No published PK data found (HFrEF 4-h IV infusion: peak at end-infusion, undetectable by 24 h) | Subcutaneous or IV injection | FDA-approved |
| Epitalon | Unknown | Subcutaneous injection | Preclinical (animal) |
| FOXO4-DRI | Unknown | Subcutaneous injection | Preclinical (animal) |
| GDF-11 | Unknown | Subcutaneous injection | Preclinical (animal) |
| Humanin | Unknown | Subcutaneous injection | Preclinical (animal) |
Values reflect figures reported in published research. Compare any peptides side-by-side →
This peptide belongs to the Anti-Aging category. View All Anti-Aging Peptides
Metabolic
From Our Affiliated Clinic
1836 Wellness is a physician-supervised clinic in Houston, TX. Discussing a compound on this page is not an offer to prescribe or supply it.
See how it works →Disclosure: The Peptide Dispatch and 1836 Wellness are commonly owned by 1836 Wellness LLC. We may benefit financially if you become a client of 1836 Wellness. Learn more.
Dosing, half-life figures, and mechanism descriptions on this page are compiled from peer-reviewed published research, with the species and study type stated where reported. Figures labeled “Dosing used in published research” describe what was given in those studies and do not constitute dosing recommendations for any human use. Each cited paper is listed with DOI and PubMed links in the References section above. Found an error? Contact us.